Malignant Peritoneal Mesothelioma, Advanced
Conditions
Keywords
Sintilimab, Bevacizumab, Pemetrexed, Cisplatin, Malignant Peritoneal Mesothelioma
Brief summary
To explore the efficacy and safety of sintilimab, bevacizumab combined with pemetrexed and cisplatin in the treatment of malignant peritoneal mesothelioma, and to explore the biomarkers related to efficacy or safety.
Detailed description
This single-arm study aims to enroll 28 patients with unresectable malignant peritoneal mesothelioma. Enrolled patients will undergo treatment with sintilimab (200 mg), bevacizumab (7.5 mg/kg), pemetrexed (500 mg/m\^2), and cisplatin (75 mg/m\^2) administered every three weeks. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria, and after six cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs. The primary outcome measure of the study is Progression-Free Survival (PFS), while secondary outcomes include Overall Survival (OS), Objective Response Rate (ORR), and Disease Control Rate (DCR).
Interventions
DRUGSintilimab, Bevacizumab , Pemetrexed , Cisplatin
Sintilimab: 200mg, bevacizumab: 7.5mg/kg, pemetrexed: 500mg/m2, cisplatin: 75mg /m2, Q3w. Tumor assessments will be performed every two cycles according to RECIST 1.1 criteria. After 6 cycles, maintenance therapy with sintilimab, bevacizumab, and pemetrexed will continue until disease progression or unacceptable toxicity occurs.
Sponsors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Fully understand the study and voluntarily sign the informed consent form; 2. Age ≥18 years old; 3. Pathologically (including histologically or cytologically) confirmed as peritoneal mesothelioma; 4. ECOG performance status of 0-1; 5. Expected survival of ≥3 months; 6. Function of vital organs must meet the following criteria (use of any blood products and cell growth factors is not allowed within 14 days prior to enrollment): Absolute neutrophil count ≥1.5×10\^9/L; Platelets ≥100×10\^9/L; Hemoglobin ≥90g/L; Total bilirubin \<1.5 times the upper limit of normal (ULN); ALT and AST \<2.5×ULN, GPT ≤1.5×ULN; Serum creatinine ≤1×ULN; Creatinine clearance rate \>60 ml/min (Cockcroft-Gault formula); 7. Women of childbearing potential must have a negative serum pregnancy test within 7 days before enrollment and agree to use appropriate contraception during the trial and for 8 weeks after the last dose of trial medication; for men, must be surgically sterilized or agree to use appropriate contraception during the trial and for 8 weeks after the last dose of trial medication; 8. Have not participated in other clinical studies within 4 weeks before enrollment and during treatment. -
Exclusion criteria
1. Unable to adhere to the study protocol or procedures; 2. Vaccination with live vaccines within 4 weeks before enrollment or expected during the study period; 3. Other malignancies within the past 5 years, except for cured basal or squamous cell skin cancer, thyroid papillary carcinoma, or in situ cervical cancer; 4. Active autoimmune diseases or a history of autoimmune diseases within 4 weeks prior to enrollment; 5. Previous allogeneic bone marrow or organ transplantation; 6. Serious cardiovascular diseases within 6 months prior to enrollment, including unstable angina or myocardial infarction; 7. Allergy to study drugs or any of their excipients; 8. International Normalized Ratio (INR) \>1.5 or Partial Thromboplastin Time (APTT) \>1.5×ULN; 9. Electrolyte abnormalities of clinical significance as judged by the investigator; 10. Uncontrolled hypertension before enrollment, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg; 11. Evidence or history of significant bleeding tendency within 3 months before enrollment (bleeding \>30 mL, including hematemesis, melena, hematochezia), hemoptysis (more than 5 mL of fresh blood within 4 weeks) or a thromboembolic event (including stroke and/or transient ischemic attack) within the past 12 months; 12. Significant cardiovascular diseases of clinical importance, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass grafting within the past 6 months; congestive heart failure New York Heart Association (NYHA) class \>2; ventricular arrhythmias requiring medication; Left Ventricular Ejection Fraction (LVEF) \<50%; 13. Active or uncontrolled severe infections (≥CTCAE v5.0 Grade 2); 14. Known Human Immunodeficiency Virus (HIV) infection. Clinically significant liver disease history, including viral hepatitis \[active Hepatitis B Virus (HBV) infection must be excluded, i.e., HBV DNA positive (\>1×10\^4 copies/mL or \>2000 IU/mL); known Hepatitis C Virus (HCV) infection and HCV RNA positive (\>1×10\^3 copies/mL)\]; 15. Any other diseases, clinically significant metabolic dysfunctions, physical examination findings, or laboratory findings that, in the judgment of the investigator, make the patient unsuitable for the study drug (e.g., requiring treatment for epilepsy), could interfere with the interpretation of study results, or place the patient at high risk; 16. Urinalysis indicating urine protein ≥2+ and 24-hour urine protein \>1.0g; 17. Complications requiring long-term treatment with immunosuppressants or systemic or local use of immunosuppressive corticosteroids (more than 10mg/day of prednisone or equivalent therapeutic hormones); 18. Patients deemed unsuitable for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | 36 months | The time from the date of first administration of this regimen to the date of first documented disease progression or death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | 36 months | The time from the initiation of the first dose of medication in a patient to death from any cause. |
| Objective Response Rate (ORR) | 36 months | The proportion of patients with a comfirmed complete response or patial response using RECIST1.1. |
| Disease Control Rate (DCR) | 36 months | The percentage of patients who have achieved complete response, partial response, and stable disease to the treatment, as defined by RECIST 1.1 criteria. |
Countries
China
Contacts
Primary ContactYongkun Sun
Backup ContactYuting Fang
Outcome results
None listed